Presentations of the final data will be made during the 56th ASH Annual Meeting at the Moscone Center in Results of a Phase 1 Study of Quizartinib as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Remission following an Allogeneic Hematopoietic Stem Cell Transplant: This is the first study conducted to determine whether or not quizartinib can be safely administered as post-transplant maintenance therapy in patients with AML.
http://ift.tt/1FV0Xhd
http://ift.tt/1FV0Xhd
No comments:
Post a Comment